Kyrgyzstan Medical Device Registration: Manufacturing Site Inspection Requirements

1. Key takeaways

Manufacturing site inspections in Kyrgyzstan are triggered by the potential use risk class of the device: they apply to class 2a (sterile), class 2b and class 3 devices. The inspection period is a maximum of 90 calendar days and is not counted toward the total registration timeline. An inspection may take place inside the registration procedure (Annex 1 to Cabinet Resolution No. 513) or as an independent procedure initiated in the circulation stage (Cabinet Resolution No. 450). The 2026 draft amendment by the responsible authority further proposes recognizing favorable manufacturing inspection reports issued by competent authorities of other union member states, with confirmation from at least two member states (draft status).

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1 (manufacturing inspection stage within the registration procedure).
2. Cabinet Resolution No. 450, June 29, 2026, on approval of the Procedures for Inspections in the Field of Medical Device Circulation, issued under Article 18 part 3 paragraph 2 of Law No. 216, entering into force 10 days after official publication.
3. Article 18 of Law No. 216: the statutory authorization for inspections.
4. Explanatory materials of the draft amendment released for public consultation by the Ministry of Health of the Kyrgyz Republic in 2026:
   • Manufacturing inspections apply to devices of potential risk class 2a (sterile), 2b and 3;
   • The inspection period is a maximum of 90 calendar days and is not counted toward the total registration duration;
   • A recognition mechanism would be introduced for favorable manufacturing inspection reports issued by competent authorities of other union member states, requiring confirmation from at least two member states, in order to avoid duplicate inspections;
   • If the draft is adopted, Cabinet Resolution No. 450 of 2026-06-29 must be amended in parallel;
   • Draft status, not yet in force.
5. Article 2 of Annex 1 to Cabinet Resolution No. 513: a manufacturing site is defined as a geographically separate complex used to complete the entire manufacturing process of a device or a specific stage of it.

3. Expert insights

Insight one: the trigger is a double test of risk class plus sterile status.

The list is class 2a (sterile), class 2b and class 3. One easily missed detail: not all class 2a devices trigger an inspection; only sterile class 2a products do. Non-sterile class 2a products, for example certain non-sterile dressings and routine dental instruments, in principle do not trigger an inspection. Within the same risk class, the sterile status therefore determines whether the inspection obligation exists. When arguing the classification, companies should state the sterile status explicitly as a separate determination item.

Insight two: the statutory definition of manufacturing site defines the geographic scope of the inspection.

Article 2 of Annex 1 to Cabinet Resolution No. 513 defines a manufacturing site as a geographically separate complex used to complete the entire manufacturing process of a device or a specific stage of it. This definition has two practical consequences: first, each site involved in contract manufacturing may be inspected individually; second, different production lines within the same site belong to the same inspection object. Companies using outsourced sterilization or outsourced assembly should disclose all relevant sites completely in the dossier, to avoid supplementary inspections triggered when undisclosed sites are discovered during the inspection.

Insight three: there are two inspection scenarios, but one set of preparation materials serves both.

The inspection within registration (Annex 1 to Resolution No. 513) and the inspection within circulation (Resolution No. 450) differ in trigger and in the handling of outcomes, but their content overlaps heavily: production conditions, the quality management system, product conformity, traceability and records. Preparing once and reusing across both scenarios is the most efficient approach. We recommend assembling a standing inspection package kept by the authorized representative and updated annually.

Insight four: the two-state confirmation mechanism in the draft turns union inspection investments into a portable asset.

If the mechanism takes effect, companies that have already been inspected by competent authorities in at least two union member states and hold favorable reports may be exempt from duplicate inspection in Kyrgyzstan. For Chinese manufacturers this means that manufacturing inspections already completed under the union framework in Russia and Kazakhstan are no longer just a cost for those two markets but an asset reusable across the region. Organize and archive existing inspection reports, noting the issuing authority, date, sites covered and conclusions.

Insight five: 90 calendar days is a cap, not an expectation.

The draft explanation uses the wording of no more than 90 calendar days. This is an upper-bound constraint; the actual inspection duration depends on site readiness, inspection scheduling and subsequent corrective actions. Reserving the full cap in the schedule is prudent, but companies should not infer that every project will consume the entire 90 days.

4. Practical recommendations

First, dedicate a separate row to sterile status in the classification rationale. State the sterile status of the product explicitly in the classification document and derive the inspection obligation from it. For class 2a products this single row determines whether a 90-day inspection reserve is needed.

Second, disclose all manufacturing-related sites completely. This includes owned plants, contract manufacturers, outsourced sterilization facilities and outsourced assembly facilities. Provide a complete site list and the relevant quality agreements in the registration dossier, to avoid supplementary inspections or suspension caused by incomplete disclosure at the inspection stage.

Third, maintain one standing inspection package for both scenarios. Include: quality system certificates and the most recent audit report, site layouts and process flow diagrams, key equipment lists and calibration records, batch record samples, traceability and recall drill records, complaint and vigilance files, and training records. The authorized representative should keep the package and update it annually.

Fourth, prepare the materials for the two-state confirmation mechanism in advance. Organize the manufacturing inspection reports already completed under the union framework in Russia, Kazakhstan and other member states, and assess whether the sites covered match the Kyrgyz declaration. Once the mechanism takes effect, this material converts directly into a time advantage (draft status).

5. Verification checklist

• □ The classification rationale states explicitly whether the product is sterile, and the inspection obligation for class 2a products is derived from it;
• □ Confirm whether the product falls into class 2a (sterile), 2b or 3; if so, reserve an inspection period at the 90-calendar-day cap;
• □ All manufacturing-related sites are fully disclosed: owned plants, contract manufacturers, outsourced sterilization, outsourced assembly;
• □ A standing inspection package covering both the registration and circulation scenarios is in place, kept by the authorized representative and updated annually;
• □ Manufacturing inspection reports issued by union member states have been organized and the usability of the at least two member states confirmation assessed (draft status);
• □ In the project schedule the inspection period is tracked separately from the 50-calendar-day registration main process and never merged.

Regulatory information verified as of October 29, 2026.

Our services cover: premarket pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and vigilance system setup, import and distribution compliance, fee estimation and project budget management.

GRZAN provides regulatory registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives, covering the full pathway from route selection to post-market obligations.

The GRZAN regulatory team consists of professionals with years of hands-on experience in Eurasian Economic Union registrations and maintains a stable local collaboration network in Bishkek, Almaty, Tashkent, Moscow and other cities, working in Chinese, Russian and English. We deliver actionable solutions for the issues foreign manufacturers most often encounter in the CIS region, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are labeled as a practical estimate, and experience-based values are never presented as legal requirements.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services